FI951801A0 - CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö - Google Patents
CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttöInfo
- Publication number
- FI951801A0 FI951801A0 FI951801A FI951801A FI951801A0 FI 951801 A0 FI951801 A0 FI 951801A0 FI 951801 A FI951801 A FI 951801A FI 951801 A FI951801 A FI 951801A FI 951801 A0 FI951801 A0 FI 951801A0
- Authority
- FI
- Finland
- Prior art keywords
- molecules
- ctla4
- binding
- binding molecules
- ctla4 molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/228,208 US6090914A (en) | 1991-06-27 | 1994-04-15 | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
FI951801A0 true FI951801A0 (fi) | 1995-04-13 |
FI951801A FI951801A (fi) | 1995-10-16 |
Family
ID=22856248
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI951801A FI951801A (fi) | 1994-04-15 | 1995-04-13 | CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö |
FI20041632A FI120041B (fi) | 1994-04-15 | 2004-12-20 | Liukoisia CTLA4-molekyyleja ja niiden käyttöjä |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20041632A FI120041B (fi) | 1994-04-15 | 2004-12-20 | Liukoisia CTLA4-molekyyleja ja niiden käyttöjä |
Country Status (8)
Country | Link |
---|---|
US (1) | US6090914A (fi) |
EP (2) | EP1666498A3 (fi) |
JP (2) | JPH0847391A (fi) |
AU (1) | AU701310B2 (fi) |
CA (1) | CA2146895C (fi) |
FI (2) | FI951801A (fi) |
IL (1) | IL113343A (fi) |
NO (1) | NO322278B1 (fi) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US6824779B1 (en) * | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
US6084067A (en) * | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
KR19980066046A (ko) * | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
AU9095498A (en) * | 1997-09-19 | 1999-04-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Oligopeptide compounds |
EP0947582A1 (en) * | 1998-03-31 | 1999-10-06 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
WO2001008700A1 (en) * | 1999-07-28 | 2001-02-08 | Genetics Institute, Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1165752A4 (en) * | 1999-10-22 | 2003-02-05 | Alexion Pharma Inc | MODIFIED RECOMBINATION MOLECULE REGULATING HUMOR AND CELLULAR EFFECTOR FUNCTIONS OF THE IMMUNE SYSTEM |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CA2411962A1 (en) | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
CA2413190C (en) * | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2008200400B2 (en) * | 2001-01-17 | 2012-06-07 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
WO2002058729A2 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
EP1397153B1 (en) * | 2001-05-23 | 2008-04-02 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
PT1451224E (pt) * | 2001-12-04 | 2012-10-09 | Theramab Llc | Péptido ou proteína contendo um anel c¿- d da família de receptores cd28 |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
EP1503794B9 (en) | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
CA2485098A1 (en) * | 2002-05-02 | 2003-11-13 | University Of Connecticut Health Center | Use of heat shock proteins to enhance efficacy of antibody therapeutics |
EP1549678A4 (en) * | 2002-09-30 | 2006-01-18 | Pfizer Prod Inc | HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE |
PL377731A1 (pl) * | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Sposoby hodowli komórek ssaczych do wytwarzania białka |
PT1576182E (pt) * | 2002-12-23 | 2011-01-21 | Bristol Myers Squibb Co | Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
KR20060132541A (ko) * | 2003-08-04 | 2006-12-21 | 브리스톨-마이어스 스큅 컴퍼니 | 가용성 ctla4 분자를 사용한 심혈관 질환의 치료 방법 |
KR100545720B1 (ko) * | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
US7453291B2 (en) * | 2004-09-09 | 2008-11-18 | The Regents Of The University Of California | Switch linearized track and hold circuit for switch linearization |
CA2603970A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
EP2298815B1 (en) | 2005-07-25 | 2015-03-11 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US8110194B2 (en) | 2005-12-07 | 2012-02-07 | Medarex, Inc. | CTLA-4 antibody dosage escalation regimens |
WO2007076032A2 (en) | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
PL2612868T3 (pl) * | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosupresyjne polipeptydy i kwasy nukleinowe |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
CA2812057A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
US9688740B2 (en) | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
SG10202002577XA (en) | 2015-09-21 | 2020-04-29 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
CA2580812A1 (en) * | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
AU7107794A (en) * | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
-
1994
- 1994-04-15 US US08/228,208 patent/US6090914A/en not_active Expired - Lifetime
-
1995
- 1995-04-12 NO NO19951436A patent/NO322278B1/no not_active IP Right Cessation
- 1995-04-12 IL IL113343A patent/IL113343A/en not_active IP Right Cessation
- 1995-04-12 CA CA2146895A patent/CA2146895C/en not_active Expired - Lifetime
- 1995-04-13 EP EP05022529A patent/EP1666498A3/en not_active Withdrawn
- 1995-04-13 AU AU16458/95A patent/AU701310B2/en not_active Expired
- 1995-04-13 FI FI951801A patent/FI951801A/fi not_active Application Discontinuation
- 1995-04-13 EP EP95302477A patent/EP0682039A1/en not_active Withdrawn
- 1995-04-17 JP JP7115095A patent/JPH0847391A/ja not_active Withdrawn
-
2004
- 2004-04-07 JP JP2004113481A patent/JP2004248677A/ja active Pending
- 2004-12-20 FI FI20041632A patent/FI120041B/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL113343A (en) | 2006-09-05 |
FI120041B (fi) | 2009-06-15 |
AU701310B2 (en) | 1999-01-28 |
FI20041632A (fi) | 2004-12-20 |
JPH0847391A (ja) | 1996-02-20 |
NO951436D0 (no) | 1995-04-12 |
NO951436L (no) | 1995-10-16 |
EP0682039A1 (en) | 1995-11-15 |
NO322278B1 (no) | 2006-09-04 |
CA2146895C (en) | 2012-08-07 |
EP1666498A2 (en) | 2006-06-07 |
JP2004248677A (ja) | 2004-09-09 |
FI951801A (fi) | 1995-10-16 |
IL113343A0 (en) | 1995-07-31 |
CA2146895A1 (en) | 1995-10-16 |
EP1666498A3 (en) | 2012-11-28 |
AU1645895A (en) | 1995-10-26 |
US6090914A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI951801A0 (fi) | CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö | |
FI944824A0 (fi) | Foerfarande och anordning foer bestaemning av energiaemnesomsaettningens graensvaerden | |
FI941274A0 (fi) | Foerfarande och anordning foer montering av laettelement | |
FI944920A0 (fi) | Foerfarande och anordning foer laminering av glasskivor | |
DE9402324U1 (de) | Straßenfertiger | |
FI934857A0 (fi) | Foerriktning av bindningspar in vivo | |
DE9406683U1 (de) | Straßenfertiger | |
FI971376A0 (fi) | Trofinin och trofininmedlande proteiner | |
FI944282A0 (fi) | Foerfarande och kretsarrangemang foer foerverkligande av oemsesidig tidsanpassning foer mikroprocessoranordning och daertill kopplade styranordningar | |
FI944556A0 (fi) | Foerfarande foer producering av antracykliner och deras mellanprodukter | |
FI941339A0 (fi) | Foerfarande foer belaeggning av en produkt | |
DE9408192U1 (de) | Straßenfertiger | |
FI942533A0 (fi) | Spolvaetska och droppdoseringsfoerpackning foer kontaktlinser och anvaendning av desamma | |
FI945707A0 (fi) | Foerfarande och anordning i tillverkning av en kabel | |
FI935719A0 (fi) | Faergad kontaklens och foerfarande foer faergning av en kontaklens | |
FI945736A0 (fi) | Foerfarande och anordning foer maolning av en produkt | |
FI1916U1 (fi) | Anordning foer reglering av cirkelsaogsklingors in boerdes avstaond | |
FI973396A0 (fi) | Foerfarande och apparatur foer genomfoerande av elektrokemiska maetningar | |
DE29610441U1 (de) | Verkaufsteller | |
KR960002937U (ko) | 간이 노래연습용 부스 | |
FI944183A0 (fi) | TDMA-mottagare och foerfarande foer styrning av TDMA-mottagare | |
DE9410876U1 (de) | Straßenfertiger | |
DE9420681U1 (de) | Straßenfertiger | |
FI1676U1 (fi) | Anordningar foer maerkning och registrering av frys- och kylprodukter | |
FI941928A0 (fi) | Foerfarande foer maetning av stroemning och maetningsanordning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application lapsed |